Subscribe to RSS
DOI: 10.1055/a-1869-3563
Medikamentös-induzierte Polyneuropathien jenseits von Chemotherapeutika und Antiinfektiva
Drug-Induced Polyneuropathies Beyond Chemotherapeutic Agents and Anti-Infectives
Zahlreiche in der klinischen Routine eingesetzte Wirkstoffe jenseits von Chemotherapeutika und Antiinfektiva können eine Polyneuropathie verstärken oder hervorrufen. Kenntnis darüber, welche Medikamente mit Polyneuropathien assoziiert sind sowie über Risikofaktoren seitens der Patienten können die Häufigkeit reduzieren. Bei entsprechendem Risiko sollten alternative Präparate eingesetzt oder die Indikation zur Therapie generell überdacht werden.
Abstract
Numerous drugs besides chemotherapeutic agents and anti-infectives that are regularly used in clinical routine can exacerbate or cause polyneuropathy. Knowledge about which substances are associated with polyneuropathies and patients’ risk factors can likely reduce the incidence of drug-induced polyneuropathies. In case of increased risk, alternative substances should be chosen or the indication for therapy should be reevaluated.
Publication History
Article published online:
07 September 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Jain KK. Drug-induced neurological disorders. [4. Auflage]. Berlin: Springer; 2021
- 2 Block F, Prüter C. Medikamentös induzierte neurologische und psychiatrische Störungen. Heidelberg: Springer Medizin Verlag; 2006
- 3 Grantz M, Huan MC. Unusual peripheral neuropathies. Part I: extrinsic causes. Semin Neurol 2010; 30: 387-395 DOI: 10.1055/s-0030–1267282.
- 4 Jin PH, Shin SC. Neuropathy of connective tissue diseases and other systemic diseases. Semin Neurol 2019; 39: 651-668 DOI: 10.1055/s-0039–1688989.
- 5 Karam C, Dyck PJ. Toxic neuropathies. Semin Neurol 2015; 35: 448-457 DOI: 10.1055/s-0035–1558977.
- 6 Pratt RW, Weimer LH. Medication and toxin-induced peripheral neuropathy. Semin Neurol 2005; 25: 204-216 DOI: 10.1055/s-2005–871329.
- 7 Manji H. Drug-induced neuropathies. Handb Clin Neurol 2013; 115: 729-742 DOI: 10.1016/b978–0-444–52902–2.00042–4.
- 8 Pestronk A. Pestronk A. Toxic neuropathies.
- 9 Li Y. Axonal sensorimotor polyneuropathies. Continuum (Minneap Minn) 2017; 23: 1378-1393 DOI: 10.1212/con.0000000000000514.
- 10 Jones MR, Urits I, Wolf J. et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol 2020; 15: 38-48 DOI: 10.2174/1574884714666190121154813.
- 11 Niimi N, Takaku S, Yako H. et al. Drug-induced demyelinating neuropathies. Adv Exp Med Biol 2019; 1190: 357-369 DOI: 10.1007/978–981–32–9636–7_23.
- 12 England JD, Asbury AK. Peripheral neuropathy. Lancet 2004; 363: 2151-2161 DOI: 10.1016/s0140–6736(04)16508–2.
- 13 Toledano M. Toxin-induced neuropathies. Neurol Clin 2020; 38: 749-763 DOI: 10.1016/j.ncl.2020.06.002.
- 14 Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005; 18: 574-580 DOI: 10.1097/01.wco.0000180158.34713.aa.
- 15 Peltier AC, Russell JW. Advances in understanding drug-induced neuropathies. Drug Saf 2006; 29: 23-30 DOI: 10.2165/00002018–200629010–00002.
- 16 Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003; 3: 86-92 DOI: 10.1007/s11910–003–0043–8.
- 17 Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009; 9: 69-75 DOI: 10.1007/s11910–009–0011-z.
- 18 Grisold W, Carozzi VA. Toxicity in peripheral nerves: an overview. Toxics 2021; 9 DOI: 10.3390/toxics9090218. PMID: 34564369; PMCID: PMC8472820
- 19 Manji H. Toxic neuropathy. Curr Opin Neurol 2011; 24: 484-490 DOI: 10.1097/WCO.0b013e32834a94b6.
- 20 Miller JW. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: clinical implications. Adv Nutr 2018; 9: 511s-518s DOI: 10.1093/advances/nmy023.
- 21 Stübgen JP. Drug-induced dysimmune demyelinating neuropathies. J Neurol Sci 2011; 307: 1-8 DOI: 10.1016/j.jns.2011.05.010.
- 22 Diezi M, Buclin T, Kuntzer T. Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management. Curr Opin Neurol 2013; 26: 481-488 DOI: 10.1097/WCO.0b013e328364eb07.
- 23 Kushlaf HA. Emerging toxic neuropathies and myopathies. Psychiatr Clin North Am 2013; 36: 209-218 DOI: 10.1016/j.psc.2013.02.002.
- 24 Little AA, Albers JW. Clinical description of toxic neuropathies. Handb Clin Neurol 2015; 131: 253-296 DOI: 10.1016/b978–0-444–62627–1.00015–9.
- 25 Valentine WM. Toxic peripheral neuropathies: agents and mechanisms. Toxicol Pathol 2020; 48: 152-173 DOI: 10.1177/0192623319854326.
- 26 Finsterer J, Löscher WN, Wanschitz J. et al. Orphan peripheral neuropathies. J Neuromuscul Dis 2021; 8: 1-23 DOI: 10.3233/jnd-200518.
- 27 Farhad K, Traub R, Ruzhansky KM. et al. Causes of neuropathy in patients referred as “idiopathic neuropathy”. Muscle Nerve 2016; 53: 856-861 DOI: 10.1002/mus.24969.
- 28 Gorzel KM, Dafotakis M, Holtbernd F. Nicht zum Lachen: eine Begleiterscheinung der Corona-Pandemie. Klinische Neurophysiologie 2021; 52: 213-214 DOI: 10.1055/a-1524–8155.